Kernkonzepte
Early screening for type 1 diabetes can delay clinical manifestation and improve outcomes.
Zusammenfassung
The article discusses the debate between early screening and education for type 1 diabetes management. It highlights the benefits of screening using autoantibodies, the importance of education and care, the potential of preventive therapies like teplizumab, and the skepticism surrounding screening. The discussion also covers the efficacy and side effects of teplizumab, alternative therapeutic options, and the impact of education on reducing diabetic ketoacidosis rates.
Key Highlights:
- Teplizumab delays type 1 diabetes manifestation by 3 years.
- Screening for type 1 diabetes using autoantibodies can identify early stages.
- Education and care are crucial for effective screening and management.
- Debate on the benefits of screening versus education for type 1 diabetes.
- Severe side effects of teplizumab include lymphopenia and infections.
- Alternative therapies like high-dose oral insulin and verapamil are being explored.
Statistiken
Teplizumab delays clinical diabetes manifestation by 3 years on average.
0.3% of children screened for type 1 diabetes had at least two autoantibodies.
The DKA rate in Germany has remained between 20% and 25% for the last two decades.
Zitate
"Preventing type 1 diabetes is still not possible, we can only delay it." - Beate Karges
"Type 1 diabetes can be delayed with an immune intervention, but to do so, we must also accept possible severe side effects in an otherwise healthy child." - Beate Karges